Last update Aug. 6, 2017
Used in the treatment of hepatitis C, usually in combination with other antivirals.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016, Spera 2016), other experts believe that treatment with Paritaprevir, on its own or in combination with Ombitasvir and ritonavir or with Ombitasvir, Ritonavir and Desabuvir is not contraindicated during breastfeeding (LactMed 2016).
We do not have alternatives for Paritaprevir.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.